Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chemotherapy + avelumab + talazoparib
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Chemotherapy + avelumab + talazoparib is an investigational combination regimen that was evaluated for the first-line treatment of advanced ovarian cancer. The regimen consists of avelumab (an anti-PD-L1 monoclonal antibody), talazoparib (a PARP1/2 inhibitor), and platinum-based chemotherapy. The therapeutic strategy involved an initial phase of chemotherapy combined with avelumab to induce tumor cell death and increase antigen presentation, followed by a maintenance phase of avelumab and talazoparib to provide sustained immune activation and inhibit DNA damage repair. The Phase 3 JAVELIN Ovarian PARP 100 trial (NCT03642132) investigating this combination was terminated in 2019 by developers Pfizer and Merck KGaA after interim results from a related study suggested the combination would not meet its primary efficacy endpoints.
- Other names
- avelumab + talazoparib + chemotherapy
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PARP16KCNH2 (Voltage-gated potassium channel subfamily H member 2)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on chemotherapy + avelumab + talazoparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chemotherapy + avelumab + talazoparib.